Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

First-line catheter ablation reduces PVC burden in paediatric population

Elaine Soliven
12 Apr 2019

The use of catheter ablation as first-line treatment reduces the number of premature ventricular complexes (PVCs) in a paediatric population, according to a study presented at EHRA 2019.

This study involved 124 paediatric patients (mean age 12 years) with symptomatic, frequent PVCs who were randomized to receive either catheter ablation (n=62) or medical therapy (n=62), with anti-arrhythmic drugs such as metoprolol 12–25 mg (n=57) or verapamil 20–160 mg (n=5). Freedom from PVCs (rate of ≤300 beats/day based on a 24-hour ECG* Holter monitoring) at 12 months was the study’s primary outcome. Patients were followed up at 1, 3, 6, and 12 months. [EHRA 2019, abstract 847]

At 12 months of follow-up, patients who underwent catheter ablation achieved a significantly higher rate of freedom from PVCs than those who had medical therapy (77.4 percent vs 48.4 percent; p=0.001), with a 62 percent significant reduction in the incidence of PVC (hazard ratio, 0.38; p=0.002).

Patients in the catheter ablation group also had a significantly lower number of PVCs (2,853 vs 11,591; p<0.001) and incidence of PVC burden (2.6 percent vs 10.4 percent; p<0.001) than those in the medical therapy group.

Researchers found that catheter ablation was associated with a 3 percent increase in the left ventricular ejection fraction compared with the medical therapy at 12 months (70.6 percent vs 67.6 percent; p<0.001), “which can potentially prevent left ventricular dysfunction,” said study lead author Dr Alexander Romanov from E. Meshalkin National Medical Research Center in Novosibirsk, Russia.

One patient developed a groin haematoma after the catheter ablation procedure, but this was resolved before discharged.

Fatigue, dizziness, shortness of breath during exercise, and palpitations were the most common reported symptoms of PVCs, with no serious adverse events.

Catheter ablation of frequent PVCs in paediatric population is safe and effective and is [also] associated with significant PVCs burden reduction over medical therapy,” Romanov said.

Catheter ablation of frequent, symptomatic PVCs in paediatric population as a first-line therapy is superior over medical therapy for preventing PVCs recurrence and burden without serious procedural complications,” he added.

 

*ECG: Electrocardiogram

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.